 FOSTER CITY, Calif., Oct. 11, 2022 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis NASH, today announced that management will be presenting at the H. C. Wainwright 6th Annual NASH Investor Conference on Monday, October 17 at 11:30 a.m. ET. 